Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials.

Rechallenge with anti-EGFR drugs represents a promising strategy in refractory

Déclaration de conflit d'intérêts

Ciardiello Davide: travel support from Sanofi, Bristol Myers Squibb (BMS) and Merk-Serono. Avallone Antonio: has served as advisory and speaker for Amgen and Servier. E.M.: has served as advisor and speaker for AstraZeneca, Eli Lilly, Servier, Sanofi Genzyme, Roche, Merck, Eisai, Pfizer. Pietrantonio Filippo: has served as adviser/speaker for Amgen, Roche, Lilly, Sanofi, Merck-Serono, Bayer, Servier. Received a research Grants from BMS. Cremolini Chiara: has served as adviser for Roche, Bayer, Agmen, and speaker for Roche, Bayer, Agmen, Serveir; received research founding form Merck-Serono. Fazio Nicola: Nicola Fazio is on the steering committees for Novartis, Ipsen, Merck Serono, MSD, Pharmacyclics, Incyte, Halozyme, Roche, Astellas, Pfizer, FivePrime, and BeiGene; is an advisory board member and a public speaker for Novartis, Ipsen, Pfizer, Merck Serono, Advanced Accelerator Applications, MSD, Sanofi-Aventis, and Wren Laboratories Europe. Troiani Teresa: has served as adviser and speaker for Roche, Merck-Serono, Sanofi, Servier, Novartis, Bayer. Martinelli Erika: has served as adviser and speaker for AstraZeneca, Amgen, Bayer, Merck-Serono, Roche, Sanofi, Servier, Pierre Fabre. Ciardiello Fortunato: has served as adviser and speaker for Roche, Amgen, Merck-Serono, Pfizer, Sanofi, Bayer, Servier, BMS, Cellgene, Lilly. Received institutional Research Grants form Bayer, Roche, Merck-Serono, Amgen, AstraZeneca, Takeda. All other authors have declared no conflicts of interest.